相关临床试验
44
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1912
进行中（未招募）
1
2.3%
已完成
39
88.6%
招募中
2
4.5%
Unknown
1
2.3%
撤回
1
2.3%
暂无批准数据
- A 2024 global survey by IASLC shows significant improvement in biomarker testing rates for lung cancer patients, rising from 39% to 67% since 2018, though critical barriers remain. - Cost remains the primary obstacle at 27.2%, followed by time constraints (13.9%), tissue sample quality (13.8%), and access issues (12.8%), affecting both early- and late-stage lung cancer testing. - Despite 98.3% of healthcare providers acknowledging biomarker testing's impact on outcomes, 43% report treating patients before receiving test results, highlighting ongoing implementation challenges.
- Two groundbreaking deep learning strategies presented at IASLC 2024 demonstrate high accuracy in detecting lung cancer biomarkers using whole slide images, potentially reducing testing turnaround time from 14 days. - The DeepGEM model achieved superior predictive performance across multiple genes with an AUC of 0.842 for gene mutation detection in external validation, showing particular strength in identifying EGFR and KRAS mutations. - Novel AI analysis of tumor microenvironment revealed distinct metabolic patterns associated with immunotherapy response, with tumors showing high PPP+ metabolic state demonstrating resistance to PD-1 agents.
